Post-Translational Modifications in Alcoholic Liver Disease and Cancer
The primary goal of the Tomasi Laboratory is to understand the role of post-translational modifications in the development and progression of alcoholic liver disease (ALD) and breast and liver cancers. Leading the Tomasi Lab is Maria Lauda Tomasi, PhD. Tomasi is a pioneer in the fields of sumoylation and phosphorylation in ALD, and more than five years ago she began using a proteomic approach to identify the candidate therapeutic targets. The Tomasi Lab is expanding its research to study some key sumoylated players in breast cancer under conditions of alcohol abuse as well. The lab has been using in vivo silencing of targeted proteins to slow the progression of ALD and cancer to limit the development of these diseases.
The Tomasi Laboratory is affiliated with the Cedars-Sinai Department of Medicine.